| . | P1 . | P2 . | |
|---|---|---|---|
| Age 6 yr . | Age 26 yr . | Age 14 yr . | |
| Absolute lymphocyte count (×109/liter) | 2.4 (1.1–4.5) | 1.74 (1.1–4.5) | 1.48 (1.1–4.5) |
| CD3+ T cells | |||
| Absolute (×109/liter) | 1.7 (0.75–2.51) | 1.43 (0.75–2.51) | 1.11 (0.75–2.51) |
| % | 71 (55–84) | 82.3 (55–84) | 75 (55–84) |
| CD4+ T cells | |||
| Absolute (×109/liter) | 0.94 (0.43–1.69) | 0.82 (0.43–1.69) | 0.66 (0.43–1.69) |
| % | 39 (31–60) | 47.1 (31–60) | 45 (31–60) |
| CD8+ T cells | |||
| Absolute (×109/liter) | 0.67 (0.22–1.21) | 0.52 (0.22–1.21) | 0.47 (0.22–1.21) |
| % | 28 (13–41) | 30.1 (13–41) | 32 (13–41) |
| CD16+/CD56+ NK cells | |||
| Absolute (×109/liter) | 0.12 (0.12–0.60) | 0.09 (0.12–0.60) | 0.07 (0.12–0.60) |
| % | 5 (5–27) | 4.9 (5–27) | 5 (5–27) |
| CD19+ B cells | |||
| Absolute (×109/liter) | 0.48 (0.12–0.64) | 0.23 (0.12–0.64) | 0.21 (0.12–0.64) |
| % | 20 (6–25) | 13.3 (6–25) | 14 (6–25) |
| IgE (KU/liter) | 859 (0–48) | 7,060 (0–81) | 795 (0–81) |
| IgG (g/liter) | 4.5 (4.9–16.1) | 7.71 (6–16) | 5.3 (6–16) |
| IgG1 (g/liter) | 4 (2.3–6.4) | ||
| IgG2 (g/liter) | 0.28 (0.4–4.5) | ||
| IgG3 (g/liter) | 0.78 (0.1–1.1) | ||
| IgG4 (g/liter) | <0.02 (0–0.8) | ||
| IgM (g/liter) | 0.5 (0.5–1.9) | 0.24 (0.5–1.9) | 0.3 (0.5–1.9) |
| IgA (g/liter) | 0.3 (0.4–2.0) | 0.91 (0.8–2.8) | 0.6 (0.8–2.8) |
| Hib IgG (µg/ml) | <0.15 (prevaccine)a | 3.01a | |
| Pneumococcal titer (IU/ml) | 38b | ||
| Tetanus IgG (IU/ml) | >0.1c | ||
| NBT (%) | 0/96 | 100 | |
| DHR | |||
| Resting (%) | 6 (Control, 2) | ||
| Stimulated (%) | 100 (Control, 100) | ||
| IL-6 (pg/ml) | 830.8 (0–7) | ||
| IL-6 (pg/ml) | 205.6 (0–7) | ||
| . | P1 . | P2 . | |
|---|---|---|---|
| Age 6 yr . | Age 26 yr . | Age 14 yr . | |
| Absolute lymphocyte count (×109/liter) | 2.4 (1.1–4.5) | 1.74 (1.1–4.5) | 1.48 (1.1–4.5) |
| CD3+ T cells | |||
| Absolute (×109/liter) | 1.7 (0.75–2.51) | 1.43 (0.75–2.51) | 1.11 (0.75–2.51) |
| % | 71 (55–84) | 82.3 (55–84) | 75 (55–84) |
| CD4+ T cells | |||
| Absolute (×109/liter) | 0.94 (0.43–1.69) | 0.82 (0.43–1.69) | 0.66 (0.43–1.69) |
| % | 39 (31–60) | 47.1 (31–60) | 45 (31–60) |
| CD8+ T cells | |||
| Absolute (×109/liter) | 0.67 (0.22–1.21) | 0.52 (0.22–1.21) | 0.47 (0.22–1.21) |
| % | 28 (13–41) | 30.1 (13–41) | 32 (13–41) |
| CD16+/CD56+ NK cells | |||
| Absolute (×109/liter) | 0.12 (0.12–0.60) | 0.09 (0.12–0.60) | 0.07 (0.12–0.60) |
| % | 5 (5–27) | 4.9 (5–27) | 5 (5–27) |
| CD19+ B cells | |||
| Absolute (×109/liter) | 0.48 (0.12–0.64) | 0.23 (0.12–0.64) | 0.21 (0.12–0.64) |
| % | 20 (6–25) | 13.3 (6–25) | 14 (6–25) |
| IgE (KU/liter) | 859 (0–48) | 7,060 (0–81) | 795 (0–81) |
| IgG (g/liter) | 4.5 (4.9–16.1) | 7.71 (6–16) | 5.3 (6–16) |
| IgG1 (g/liter) | 4 (2.3–6.4) | ||
| IgG2 (g/liter) | 0.28 (0.4–4.5) | ||
| IgG3 (g/liter) | 0.78 (0.1–1.1) | ||
| IgG4 (g/liter) | <0.02 (0–0.8) | ||
| IgM (g/liter) | 0.5 (0.5–1.9) | 0.24 (0.5–1.9) | 0.3 (0.5–1.9) |
| IgA (g/liter) | 0.3 (0.4–2.0) | 0.91 (0.8–2.8) | 0.6 (0.8–2.8) |
| Hib IgG (µg/ml) | <0.15 (prevaccine)a | 3.01a | |
| Pneumococcal titer (IU/ml) | 38b | ||
| Tetanus IgG (IU/ml) | >0.1c | ||
| NBT (%) | 0/96 | 100 | |
| DHR | |||
| Resting (%) | 6 (Control, 2) | ||
| Stimulated (%) | 100 (Control, 100) | ||
| IL-6 (pg/ml) | 830.8 (0–7) | ||
| IL-6 (pg/ml) | 205.6 (0–7) | ||
Abnormal results are shown in bold. Numbers in parentheses indicate reference values of the corresponding measurements. DHR, dihydrorhodamine; Hib, H. influenza bacteria; NBT, nitroblue tetrazolium.
Minimum protective level, 0.15 µg/ml; optimum protective level, 1.0 µg/ml.
A value of 60 represents the 25th centile of the normal population.
Minimum protective level, 0.01 IU/ml; optimum protective level, 0.1 IU/ml; long-term protective level, >1.0 IU/ml.